Bookmark
Forward
Explore Curated Studies Results
Explore Literature Results
Explore Clinical Trials Results
QuickView for GilEnyA (compound)
Most Correlated Studies
- Expression data from human Jurkat T cells exposed to 31 compounds
- Acute myeloblastic leukemia Kasumi-1 cells treated with sphingosine analogue FTY720
- Breast cancer MCF7 cells treated with sphingosine-1-phosphate, FTY720 or SAHA
- Hippocampi of fingolimod-treated mice after fear consolidation test
- Lung expression profiling in irradiated mice treated with (S)-FTY-phosphonate, SEW-2871, and FTY-720
Most Relevant Literature
- Soft Palate Malignant Melanoma as an Adverse Effect of Fingolimod in Multiple Sclerosis: A Case Repo…
- CDX-modified chitosan nanoparticles remarkably reduce therapeutic dose of fingolimod in the EAE mode…
- The consequences of switching from Gilenya® to generics for fingolimod.
- Multiple Sclerosis Relapses Following Cessation of Fingolimod.
- Molluscum contagiosum in the setting of Fingolimod: The experience at one institution.
Most Relevant Clinical Trials
- Gilenya in Amyotrophic Lateral Sclerosis (ALS)
- Gilenya's Impact on Cognitive Function and Thalamic Volumes
- The Gilenya Pregnancy Registry
- Biologic Basis for Multiple Sclerosis Disease Progression in RRMS Patients Treated With Gilenya
- Assessing Induction of Type II (M2) Monocytes/Macrophages in Patients Receiving Gilenya.
